No registrations found.
ID
Source
Brief title
Health condition
Cancer, chemotherapy, drug-drug interactions, oncology, pharmacology, risk factors.
Sponsors and support
2.Stichting Coolsingel
Intervention
Outcome measures
Primary outcome
Prevalence of drug-drug interactions (DDI's) and the clinical consequence of these DDI's.
Secondary outcome
The secondary objective is to obtain more insight into possible determinants for the occurrence of these DDIs.
Background summary
Drug-drug interactions in patients using anticancer drugs are common, although not always these are recognized by pharmacists and physicians. These interactions may have serious consequences for the number and severity of side-effects and efficacy of treatment. As side-effects could potentially be lethal, and efficacy could be diminished by such interactions, it is extremely important to visualize drug-drug interactions (DDI) on forehand. With a firm increase in available (and chronically used) oral anticancer agents during recent years, the risk for DDIs has become even more important for clinical practice. Outcomes of this study may help physicians and pharmacists to create awareness of DDIs and should lead to a closer collaboration between them to identify and manage these DDIs.
Study objective
We assess the prevalence and seriousness of DDIs among ambulatory cancer patients on anti-cancer treatment.
Study design
1-2-2012: Start study inclusion;
1-2-2013: End study inclusion;
1-2-2013 till 1-2-2013: Analysing, writing.
Intervention
Medication review in oncology.
´s-Gravendijkwal 230
Roelof Leeuwen, van
Rotterdam 3015 CE
The Netherlands
+31 (0)10 7033202
r.w.f.vanleeuwen@erasmusmc.nl
´s-Gravendijkwal 230
Roelof Leeuwen, van
Rotterdam 3015 CE
The Netherlands
+31 (0)10 7033202
r.w.f.vanleeuwen@erasmusmc.nl
Inclusion criteria
All ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who are receiving one or more (oral) anti-cancer therapies, are included in the study.
Exclusion criteria
1. The use of experimental trial agents;
2. Age <18 years;
3. The use of anti-cancer drugs for non-malignant diseases.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3591 |
| NTR-old | NTR3760 |
| Other | METC : 12.12151 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |